This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
In a phase I/II study, chimeric antigen receptor T cells produced complete remissions in 88% of patients with refractory or relapsed follicular lymphoma, all of whom remained in remission after a median of 2 years of follow-up. The treatment induced cytokine release syndrome and neurotoxicity in 50% of patients, but none developed side effects more severe than grade 2.
- ©2019 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
September 2019
Volume 9, Issue 9
Volume 9, Issue 9
CAR T-cell Therapy Yields Durable Remissions in FL
Jump to section
Advertisement